Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 +1.37%83 Days Inventory is 213.07 as of Dec. 2025, which is 21% above its 10-year median of 176.07. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$33.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 65.91% on this metric.
The historical rank and industry rank for Synmosa Biopharma's Days Inventory or its related term are showing as below:
ROCO:4114'
s Days Inventory Range Over the Past 10 Years
Min: 156 Med: 176.07 Max: 222.26
Current: 205.72
During the past 13 years, Synmosa Biopharma's highest Days Inventory was 222.26. The lowest was 156.00. And the median was 176.07.
ROCO:4114's Days Inventory is ranked worse than 65.91% of 921
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs ROCO:4114: 205.72
Synmosa Biopharma's Days Inventory
increased
from Dec. 2024 (180.48) to Dec. 2025 (213.07).
It might indicate that Synmosa Biopharma's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Synmosa Biopharma's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.43.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Synmosa Biopharma's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 1.35.
Synmosa Biopharma (ROCO:4114) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Synmosa Biopharma's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Synmosa Biopharma's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Synmosa Biopharma Days Inventory Related Terms
Synmosa Biopharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synmosa Biopharma (ROCO:4114) has a Days Inventory of 213.07 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Synmosa Biopharma and its competitors. This is 21% above median its historical median of 176.07. Over the past decade, Synmosa Biopharma's Days Inventory has ranged from 156.00 to 222.26. According to the industry distribution chart, Synmosa Biopharma ranks #607 out of 921 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Synmosa Biopharma's Days Inventory too high?
Synmosa Biopharma's current Days Inventory of 213.07 is 21% above median its 10-year median of 176.07. Over the past 10 years, this metric has ranged from a low of 156.00 to a high of 222.26. The Drug Manufacturers industry median Days Inventory is 164.48. Synmosa Biopharma's value of 213.07 is 29.5% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #607 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #607 out of 921 companies for Days Inventory. This places Synmosa Biopharma in the lower half of its industry. The industry median Days Inventory is 164.48. Synmosa Biopharma's value of 213.07 is 29.5% above this benchmark. Historically, Synmosa Biopharma's own Days Inventory has ranged from 156.00 to 222.26 over the past decade. While the company's 10-year median is 176.07 vs. the industry median of 164.48, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Days Inventory of 213.07 is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Days Inventory is 213.07, which is 21% above median its own 10-year median of 176.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.93, compared to a current price of NT$29.70 — trading 12.5% below its estimated fair value. The current Days Inventory is 213.07, which is 21% above median its 10-year median of 176.07 and 29.5% above the Drug Manufacturers industry median of 164.48. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Days Inventory is 213.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.70 is trading 12.5% below its estimated GF Value™ of NT$33.93.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Days Inventory: 213.07 (21% above median its 10-year median of 176.07)
GF Value™: NT$33.93 vs. price of NT$29.70 (12.5% below fair value)
Industry Position: 29.5% above the Drug Manufacturers median (#607 of 921)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score
Get the complete analysis for ROCO:4114
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
